Subcutaneous Daratumumab in R/R Myeloma: The COLUMBA Trial

(3:48)

Subcutaneous Daratumumab — Dr. Jonathan Kaufman | MCRT Webcast July 11

(15:9)

Subcutaneous daratumumab: combining efficacy, safety \u0026 convenience

(1:8)

Dr. Martin on Subcutaneous Administration of Daratumumab in Multiple Myeloma

(49)

Dr. Harrison on Subcutaneous Daratumumab and Isatuximab in Myeloma

(1:5)

Subcutaneous daratumumab: an update on the latest MM clinical trials

(2:39)

Subcutaneous daratumumab show benefit in patients with relapsed or refractory multiple myeloma

(1:33)

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

(5:)

Dr Sonneveld on the FDA Approval of Subcutaneous Daratumumab Plus VRd in Myeloma

(2:24)

Columba study update: subcutaneous daratumumab in R/R MM

(1:3)

Saad Usmani, MD, FACP, compares IV daratumumab and subcutaneous daratumumab

(1:39)

Dr. Usmani on Subcutaneous Delivery of Daratumumab in Myeloma

(1:48)

Practical Management of IV Daratumumab in MM

(1:47)

Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with MM

(6:48)

Clinical Impact of SubQ Daratumumab for Multiple Myeloma

(3:8)

Subcutaneous Delivery of Daratumumab

(1:55)

Exciting Subcutaneous Formulation Approval in MM

(4:27)

Community Advice: SQ Formulation of Daratumumab

(7:14)

Subcutaneous Daratumumab With Pomalidomide \u0026 Dexamethasone for Relapsed/Refractory Multiple Myeloma

(3:53)

Daratumumab and dexamethasone in the treatment of patients with myeloma and severe renal impairment

(1:22)